{"id":38110,"date":"2025-10-18T10:41:29","date_gmt":"2025-10-18T10:41:29","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/itm-announces-phase-3-compete-data-demonstrating-a-statistically-significant-higher-objective-response-rate-with-n-c-a-177lu-edotreotide-itm-11-vs-everolimus-in-patients-with-gastroenteropancreati\/"},"modified":"2025-10-18T10:41:29","modified_gmt":"2025-10-18T10:41:29","slug":"itm-announces-phase-3-compete-data-demonstrating-a-statistically-significant-higher-objective-response-rate-with-n-c-a-177lu-edotreotide-itm-11-vs-everolimus-in-patients-with-gastroenteropancreati","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/itm-announces-phase-3-compete-data-demonstrating-a-statistically-significant-higher-objective-response-rate-with-n-c-a-177lu-edotreotide-itm-11-vs-everolimus-in-patients-with-gastroenteropancreati\/","title":{"rendered":"ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<ul>\n<li>\u00a0Study data also showed prolonged progression-free survival with <sup>177<\/sup>Lu-edotreotide compared to everolimus across patient subgroups<\/li>\n<\/ul>\n<p align=\"justify\"><strong><br \/>Berlin, Germany, October 18, 2025<\/strong> \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MmM_mTPkO3TLwUrjihYUDP0qQEl3E4YOwPPNWBH-OnmxB0Gu3LKRKe06Jz-ty2xSIeMpEhnP0sAz547b-TXniTgPHeTwfbEI2CRLq8IIFxYAfGNCPsKmpiCukBmFAxuW\" rel=\"nofollow\" target=\"_blank\" title=\"ITM Isotope Technologies Munich SE\">ITM Isotope Technologies Munich SE<\/a><u> (ITM)<\/u><u>,<\/u> a leading radiopharmaceutical biotech company, today announced a higher objective response rate (ORR) and prolonged median progression-free survival (mPFS) across subgroups in patients treated with non-carrier-added (n.c.a) <sup>177<\/sup>Lu-edotreotide (also known as ITM-11 or <sup>177<\/sup>Lu-edotreotide) compared to everolimus from its Phase 3 COMPETE trial in Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Study investigator Jaume Capdevila, MD, PhD, presented the data in an oral presentation at the European Society for Molecular Oncology (ESMO) Congress, held October 17-21, 2025 in Berlin, Germany. <\/p>\n<p align=\"justify\">As announced in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x938fL_YycszLV_g0lzOMyfr7c9q8HaSoWKELhAuE2SRR8eVInTiKxS7LRs-JpbQqxqNu_Bh6CgB_Qb5EsbHa-66B8KFMiDXU7DFrsGa29XBn5UQVxHXibMkA1z8nOlOG55GuTYDOCTZZY-x5nR3iaakRMht1aERp0ck27QdHm6crPxxGGdEbbvwDi6iGOaHzdfivdch4YPAKoVWtT23PEM4lHr0f3vACkjgUrTJ7pV1krbmS-i7AgCC0UUrdPvlYvMQPuNvG0wECyIMKkAOVDpiY8tnr3vGIKnjwK2Pg9aJ6epOYeyTpNwyE2Lj3RutGzeiXpgGxveEJfyL_OfNuE6USz7SeXIfjvTuTydJwzWD9jHoGBfO1E4l9b7vVrkNDUHEEaJ0lA8Vm5TmMJUTzMLJObBHFm58bTIahgEplzo=\" rel=\"nofollow\" target=\"_blank\" title=\"January\">January<\/a> and at ENETS in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VTsSn3Vn6-PoKQic5aNDUVO6xWTGymBA72U3H4sJ1cuB6_M0LG3UW1pVjWurFO5PWHNlZPsqTqW72Wu_MfjTpH31gLoBN9zgaOa7MfImARcNgNXCpmSZ-VMxjyVEJ9s5vryCLYTMPxYqoHA3pQdPpb8DKZeiSJeUw3T700oah5MhvFwnfIhP7sEqvadLPEOjNv0TXAgm-Hnq-8na_nnBQRAEa1qSwaisx8C0vA0jgEez-_-ehD7uyGMCMHCkR_S75wao-iziDQCLMAoijEhGCvTNYKDj3YZDxmA9H7I1ldLEGwed4fdnU--XHYqyII2EtZg2s7B2_NwBtOFBjhThMuGmYQDC-mImDtg1vQvMvanFHXeOMUfFKyhE1kEbhaat0XxTwqt7k6xydBpu2WGDJDZanzhgDLZ9kDnSb07bUkoyJsQ0DPloudWqGJHa26Qk0rLZ_ka6Sof3vHoLqKiAlg==\" rel=\"nofollow\" target=\"_blank\" title=\"March 2025\">March 2025<\/a>, the Phase 3 COMPETE trial met its primary endpoint, demonstrating a statistically significant improvement in mPFS (p&lt;0.022) in patients treated with investigational radiotherapeutic agent n.c.a. <sup>177<\/sup>Lu-edotreotide compared with everolimus. The mPFS was centrally assessed by a Blinded Independent Central Review (BICR). A total of 309 patients were randomized to either <sup>177<\/sup>Lu-edotreotide (n=207) or everolimus (n=102).<\/p>\n<p align=\"justify\">Key findings included:\u00a0<\/p>\n<ul>\n<li style=\"text-align:justify;\">ORR, a key secondary endpoint, was significantly higher in the <sup>177<\/sup>Lu-edotreotide arm vs. everolimus <\/li>\n<li style=\"margin-top:0cm; margin-bottom:1pt; text-align:justify;\">mPFS, by central assessment, was longer in the <sup>177<\/sup>Lu-edotreotide arm in patient subgroups: gastroenteric NET, pancreatic NET, Grade 1, Grade 2, 1st line, 2nd line \u200b<\/li>\n<li style=\"margin-top:0cm; margin-bottom:1pt; text-align:justify;\">Frequency of patients who experienced treatment-emergent adverse events (TEAEs) leading to premature study discontinuation was lower in the <sup>177<\/sup>Lu-edotreotide arm<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse; width:900px; border-collapse:collapse ;\">\n<tr>\n<td colspan=\"3\" style=\"width:624.47px;;text-align: center ;  vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <strong>Objective Response Rate <\/strong>  <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">\u00a0  <\/td>\n<td style=\"width:174.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">  <strong><sup>177<\/sup><\/strong><strong>Lu-edotreotide (n=207) vs. Everolimus <\/strong><strong>(n=102)<\/strong>  <\/td>\n<td style=\"width:267.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">  <strong>P value, Hazard Ratio (HR)\/Confidence Interval (CI)<\/strong>  <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <strong>ORR<br \/><\/strong>Central assessment<br \/>Local assessment  <\/td>\n<td style=\"width:174.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">21.9% vs. 4.2%<br \/>30.5% vs. 8.4%  <\/td>\n<td style=\"width:267.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">p&lt;0.0001<br \/>p&lt;0.0001  <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:624.47px;;text-align: center ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <strong>Median Progression-Free Survival by Patient Subgroup (Central Assessment)<\/strong><strong><sup>1<\/sup><\/strong>  <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <strong>Primary Tumor Origin<\/strong><br \/>Gastroenteric NET <br \/>Pancreatic NET   <\/td>\n<td style=\"width:174.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">23.9 vs. 12.0 months<br \/>24.5 vs. 14.7 months  <\/td>\n<td style=\"width:267.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">p=0.090; HR 0.64, 95% CI [0.38, 1.08]<br \/>p=0.114; HR 0.70, 95% CI [0.45, 1.09]  <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <strong>Tumor Grade<sup>2<\/sup><\/strong><br \/>Grade 1<br \/>Grade 2  <\/td>\n<td style=\"width:174.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">30 vs. 23.7 months<br \/>21.7 vs. 9.2 months  <\/td>\n<td style=\"width:267.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">p=0.753; HR 0.89, 95% CI [0.42, 1.87]<br \/>p=0.003; HR 0.55, 95% CI [0.37, 0.82]  <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <strong>Prior Medical Therapy<\/strong><br \/>Treatment-na\u00efve (1<sup>st<\/sup> line)<br \/>Prior therapy (2nd line)  <\/td>\n<td style=\"width:174.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">NR<sup>3<\/sup> vs.18.1 months<br \/>23.9 vs. 14.1 months  <\/td>\n<td style=\"width:267.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">p=0.249; HR 0.60, 95% CI [0.25, 1.45]<br \/>p=0.039; HR 0.68, 95% CI [0.47, 0.98]  <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:624.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <em><sup>1<\/sup><\/em><em>Unstratified statistics <sup>2<\/sup>Tumor grade was determined locally, per protocol <sup>3<\/sup> Not reached\u00a0 <\/em>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:624.47px;;text-align: center ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <strong>Premature Study Discontinuations <\/strong>  <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">  <strong>Frequency of Trial Discontinuations Related to Treatment-Emergent Adverse Events (TEAEs) <\/strong>  <\/td>\n<td style=\"width:174.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">1.8% vs. 15.2%  <\/td>\n<td style=\"width:267.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">\u00a0  <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\u201c<em>The prolonged PFS observed across patient subgroups reinforces the consistent therapeutic effect and safety profile of <sup>177<\/sup>Lu-edotreotide<\/em>,\u201d <em>said <strong>Dr. Capdevila, senior medical oncologist at Vall d&#8217;Hebron University Hospital, Barcelona<\/strong>. <\/em>\u201c<em>Importantly, the low rate of discontinuations due to treatment-emergent adverse events underscores <sup>177<\/sup>Lu-edotreotide\u2019s tolerability.<\/em>\u201d<\/p>\n<p align=\"justify\">\u201c<em>These additional results, in particular meeting a key secondary endpoint of objective response rate, reinforce <sup>177<\/sup>Lu-edotreotide\u2019s potential as an important treatment option for GEP-NET patients<\/em>,\u201d <em>said <strong>Dr. Andrew Cavey, chief executive officer of ITM<\/strong><\/em>. \u201c<em>The COMPETE trial demonstrated that many patients experienced partial or complete responses with <sup>177<\/sup>Lu-edotreotide.<\/em>\u201d<\/p>\n<p align=\"justify\">Recently, ITM presented dosimetry <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J7dIsMxhgAmhlMjVPPvwTt2-Uvvk0Uz0-lMId6krb3qhknMem2zWuAN5iuDZzVBZ6NRU77pCRmehgSkoKqmQKqtXOKkAT-gG5X8QEGC1OHj2k9deb7FpB36ufiXay4U9tbxdiJSdWuhR78259aMrpttkXPosCUVuwicC95DOem-t0V8LgQAY9qe7fgdkED3KfgenBgUzgULut_vnQPYSZkt-01ts22xbpAfOtFD6Eni-RMfa8G8pGy39YsEpTIih9zp9_DtnXxiE6v1bW2WVRfSkVK4wApMJEpRrjsjLvQcXDdxTHDBgfGHzLe7zJcxZw_alTf3TOldrUgUDcvIX556WOw5atcH-21afm9Tnh6dMFqCpyQHdx2KIKVQAwtXyosQpbcSBPbGdBk09GNISBaHwiuSYxfWcg2gdjYIS7ubopLONOUSLHqpJiin3sED1A4CiakAUwWiCM0E6MNzWVg==\" rel=\"nofollow\" target=\"_blank\" title=\"data\">data<\/a> from the COMPETE trial in an oral presentation at the European Association of Nuclear Medicine (EANM) Annual Congress, in Barcelona, Spain. The data showed that <sup>177<\/sup>Lu-edotreotide delivered targeted radiation to tumors while minimizing exposure to healthy tissue, supporting its efficacy and safety profile. The presentation by Dr. Emmanuel Deshayes, COMPETE study investigator and nuclear medicine physician, received the Marie Curie Award, in recognition of exceptional scientific quality and contribution to the field of nuclear medicine.<\/p>\n<p><strong><u>Oral Presentation Information:<br \/><\/u><\/strong><strong>Title<\/strong>: \u201cEfficacy, safety and subgroup analysis of <sup>177<\/sup>Lu-edotreotide vs everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial\u201c<strong><br \/><\/strong><strong>Date and Time<\/strong><strong>:<\/strong> October 18, 2025, 11:05-11:15 am CEST, followed by Q&amp;A and discussion<br \/><strong>Session and Room Number<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_qDOaYEXFxbwN2paccEz3oxcsHa_sSDCITk2tmPA2bOOtrv4KawHHu2vVHPFC0VfYvVH12KLpF94QjTucd4RYX_itX-BgpBMFtVERWNZ65dt9r8K9i6v-T9BGj_LJS5qahppWaPxPP5Q9DvQhGoztf1c7M5VHq9XGnVBwsag3e2XzF1p55dS8qnf5WcVaztP\" rel=\"nofollow\" target=\"_blank\" title=\"NETs and endocrine tumours\">NETs and endocrine tumours<\/a> Proffered Paper session<strong>, <\/strong>Karlsruhe Auditorium &#8211; Hall 5.2<br \/><strong>Presenter<\/strong>: Jaume Capdevila, MD, PhD, study investigator and senior medical oncologist at Vall d&#8217;Hebron University Hospital, Barcelona<\/p>\n<p><strong>About the COMPETE Trial<br \/><\/strong>The COMPETE trial (NCT03049189) evaluated\u00a0<sup>177<\/sup>Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreaticneuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with\u00a0<sup>177<\/sup>Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus.\u00a0<sup>177<\/sup>Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors.<\/p>\n<p align=\"justify\"><strong>About GEP-NETS<br \/><\/strong>Neuroendocrine tumors (NETs) are a rare form of cancer, with an estimated 8 new cases per 100,000 individuals diagnosed each year in the U.S. and 9 cases per 100,000 in Europe. The incidence of NETs has steadily increased over recent decades, resulting, in part, from improved diagnosis. Gastroenteropancreatic neuroendocrine tumors (GEP-NETS) originate in the neuroendocrine system and are made up of nerve cells and hormone-producing cells. They can occur anywhere in the GI tract and pancreas, including the stomach, small intestine, colon, rectum, and appendix. There is still a high unmet medical need for treatment options, as many patients are asymptomatic and diagnosed at a late stage with metastatic disease.<\/p>\n<p align=\"justify\"><strong>About ITM Isotope Technologies Munich SE<br \/><\/strong>ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company\u2019s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QiHc9tUNRS4sF3X7XrXdfSgziXNN8UMom9lHnbWNPXN5lpCg_qm7HHd5pNn1tqyhs9OkKju3-_0iHirF59ogP_q0u7-rwAejcpKNwuIWAAm_NT28n5cZ5g40nGgpmPOwHdzh9BeVxMs-K1A-lh-jPnV679Qu7fuXN2M2O2_lMgsbwSW-ng1NAHPlZ-StarMKlSn1l9NbF3C18l_iIENfg760RLAqyDzmpoM8fitd_eRCiyRghWpPgy8t5ycvAxitgiNURpwCbtUDnOpaHZRiRg==\" rel=\"nofollow\" target=\"_blank\" title=\"www.itm-radiopharma.com\">www.itm-radiopharma.com<\/a><\/p>\n<p><strong>ITM Contacts<\/strong><strong>\u00a0<\/strong><br \/><strong>Corporate Communications<\/strong><br \/>Kathleen Noonan\/Julia Westermeir<br \/>Phone: +49 89 329 8986 1500<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jshrkB2ZuoFnsvc_78vMrPtdb06IfBTHsbB_6XMF2MNfl2Jn1KGuW2sVVq-DwVwVxU_PIEggxG3p3hR7qchCDAZJYIcwLD0ozIH8MngSP1pvcG9IRfvh8QRWuErDBnD9F7alBf8I0umhQpxbg8BY_g==\" rel=\"nofollow\" target=\"_blank\" title=\"communications@itm-radiopharma.com\">communications@itm-radiopharma.com<\/a><\/p>\n<p><strong>Investor Relations<\/strong><br \/>Ben Orzelek<br \/>Phone: +49 89 329 8986 1009<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PFIaOTmtk-Kf4umBFCzonwrQj0DdmoBHKNM8k6R2aE3TTy5IVvA7HCSdGzvbUIwbd86ADe6Pn--dCjbLckUPwBr4j9A751bETI9c9rEpwUfm2QQx2gnyd27P0ZH18aW9\" rel=\"nofollow\" target=\"_blank\" title=\"investors@itm-radiopharma.com\">investors@itm-radiopharma.com<\/a><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=gqKsufbvhfM13vY9GgVRmf4s66FmOVFC9ytw-BLS4bRVkumSoFXaVIfBtRPhxjl6d67R0RsaHeHgvspSrHeMnmDaXXpP2s66LYOwrYpUemijeGVih-vLrodX8F1pEg4G9YCsJSy2e-1HHzCLjq2A32JdanbEyrxtouJctWx18BdHYWprJ5ettxTiTwFZ1kRL-4Iwl_AGkwbum_V6TtPGCuK8PPjp7rRjV7UHR2H54mPnpOaJHOuZxYBuhot6TPDHZWMk4ZH5eo5fpEYRtUGtKkadPIKzd25aMw-roY8KEthLRI5z7HSkZYikdVy6j_h1D0htzhwuUyusC42jb7LlIbEuQqUQFt2m1Xy4BCc02fi2fDVtbe0OxWdiWS66TAy-8nY018V3zc4JAIq7gKi-yNt7o5gIUUQ5QBB0itl2eIrJWVNVTiWRLUi-KHVYUPpVPdn-IObvWOmCgHCtrKJ4lAg8K5wWoepcPBNB0QL3pts=\" title=\"20251018_ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025\" rel=\"nofollow\">20251018_ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025<\/a>\n      <\/li>\n<\/ul>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 \u2013 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a higher objective response rate (ORR) and prolonged median progression-free survival (mPFS) across subgroups in patients treated with non-carrier-added (n.c.a) 177Lu-edotreotide [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":38111,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/3411c2bd-01a5-4d06-ad90-4a6e168bad61","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-38110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/38110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=38110"}],"version-history":[{"count":0,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/38110\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/38111"}],"wp:attachment":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=38110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=38110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=38110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}